Stakeholder views of managed entry agreements: A literature review of national studies.

ABSTRACT: Access to highly expensive and innovative medicine is a challenge. Managed entry agreements/ arrangements (MEAs) consist of various forms of confidential agreements between pharmaceutical manufacturers and payers (hospitals, social insurance), which are mainly negotiated when there is uncertainty of the actual clinical benefit of the medicines, but high public expenditures are required. Continued and expanding use of these schemes requires a greater understanding of payer perceptions, experience, and orientation towards their current and future use. This literature review aimed to identify the stakeholders' concerns with regards to MEAs. A total of 20 articles were identified between 2007 and 2018. MEAs are mostly studied in the first world countries, whereas limited documentation is avail

SUBMITTER: Thanimalai S 

PROVIDER: S-EPMC10297797 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature